We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Vital Biosciences Unveils Revolutionary POC Lab Testing Platform

By LabMedica International staff writers
Posted on 26 Jul 2023

Vital Biosciences (Toronto, ON, Canada) is making waves at AACC 2023 with the introduction of its game-changing product, the VitalOne. More...

This groundbreaking innovation with the potential to completely redefine diagnostics was unveiled to thousands of laboratory experts at the AACC annual gathering. Furthermore, VitalOne was recognized as the Audience Choice winner at this year's AACC Disruptive Technology Award.

For years, routine lab testing has been a cornerstone of clinical guidelines. Currently, medical decisions rely on laboratory test results 70% of the time. However, it's concerning that nearly 30% of electronic lab orders remain unfulfilled. For instance, about 20% of American adults with diabetes remain undiagnosed, and a staggering 80% of prediabetic individuals are oblivious to their condition. Preventing chronic diseases such as hyperlipidemia, type 2 diabetes, or congestive heart failure is best achieved through early detection and intervention. Unfortunately, the existing testing, diagnosis, and treatment process is not universally accessible.

The VitalOne aims to democratize blood diagnostics by making over 50 lab-grade tests — covering 95% of routine lab orders — available at primary care locations, all packaged within a device no bigger than a desktop computer. With VitalOne, physicians can conduct tests, diagnose, and treat patients all in one appointment, with results obtained in 20 minutes. The underlying technology has been rigorously tested and validated against thousands of samples in comparison to gold-standard instruments, through collaborations with Vital's lab partners.

Vital is redefining point-of-care testing with the development of the VitalOne, envisaging a future where patients do not need to sacrifice work hours, commute between their primary care doctor and a lab, or endure days of waiting to discuss their results. Bridging this gap will make diagnostics more accessible and speed up clinical interventions, helping prevent adverse outcomes and disease progression. VitalOne is currently in its late-stage product development and is yet to be made commercially available. Additional clinical studies are scheduled for later this year. Moreover, Vital is keen on forming partnerships with industry, academia, and the laboratory medicine community for further performance evaluations and feedback.

“We started Vital to make high-quality care more accessible to millions of people and realized how limited we were by our current diagnostic infrastructure,” said Vasu Nadella, CEO and Co-Founder of Vital Biosciences. “We seek to disrupt the USD 85 billion diagnostics industry by bringing lab-grade diagnostics everywhere and eliminating the impediments to proactive and accessible care.”

“We live in a world where you can order a pizza and have it delivered in 20 minutes but your lab results take days. That’s not okay,” added Mounir Koussa, Co-Founder and VP of Research and Development at Vital. “We want to ensure that diagnostics are available wherever and whenever they are needed, and that testing never becomes an impediment to treatment and care.”

Related Links:
Vital Biosciences


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
PSA Assay
CanAg PSA EIA
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The discovery of early markers for ovarian cancer that would have improved sensitivity could aid detection (Photo courtesy of Adobe Stock)

Highly Accurate Biomarkers Could Detect Ovarian Cancer Before Clinical Diagnosis

Ovarian cancer is a deadly and challenging disease, primarily because early detection is difficult. Most women (70-75%) are diagnosed only after the cancer has already spread, which significantly reduces... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.